Download presentation
Presentation is loading. Please wait.
Published byCollin Ross Modified over 6 years ago
1
Successful Osimertinib Rechallenge after Severe Osimertinib-Induced Hepatotoxicity
Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology Volume 12, Issue 5, Pages e61-e63 (May 2017) DOI: /j.jtho Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions
2
Figure 1 (A and B) Computed tomography images before treatment with osimertinib. (C and D) Computed tomography images at the time of grade 4 hepatotoxicity showed a significant reduction of tumor size in the lungs, liver, and pleural effusion. Journal of Thoracic Oncology , e61-e63DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions
3
Figure 2 Brain magnetic resonance imaging and chest computed tomography images before and after osimertinib rechallenge. (A and B) Images before osimertinib rechallenge. (C and D) At 5 months after osimertinib rechallenge, brain metastases, pulmonary tumor, and pleural effusion had decreased in size. Journal of Thoracic Oncology , e61-e63DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.